



12 January 2022

## Zelira receives \$1.2 million cash R&D Tax Incentive



### \$1.2M TAX INCENTIVE TO SUPPORT GROWTH OF ZELIRA'S PORTFOLIO OF PRODUCTS

#### Key Highlights



Zelda receives a \$1,292,000 cash refund under the Australian Federal Government's R&D Tax Incentive Scheme.



Funds received will be used to support Zelira's portfolio of products recently launched into global markets and to advance its ongoing clinical development programmes.

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, advises that it has received a \$1,292,000 cash refund under the Federal Government's Research and Development Tax Incentive Scheme.

The R&D Tax Incentive Scheme is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The funds will be used to support the growth in recent launched products including Zenivol™ for Insomnia, HOPE™ for Autism and a new CBD-Toothpaste into global markets, and also to advance Zelira's ongoing clinical and product development programs.

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.



For further information  
please contact

#### Company

Dr Oludare Odumosu  
Managing Director & CEO  
☎ +1 909 855 0675  
✉ oodumosu@zeliratx.com

#### Investors

Ronn Bechler  
Executive Chairman, Market Eye  
☎ +61 400 009 774  
✉ ronn.bechler@marketeye.com.au

#### About Zelira Therapeutics

##### Australia

Level 3, 101 St Georges Terrace  
Perth WA 6000, AUSTRALIA  
☎ +61 8 6558 0886  
Fax: +61 8 6316 3337  
✉ enquiries@zeliratx.com  
**www.zeliratx.com**  
ACN 103 782 378

##### USA

5110 Campus Drive, Suite 150  
Plymouth Meeting, PA 19462  
United States Of America  
☎ +1 484-630-0650

#### About Zelira [www.zeliratx.com](http://www.zeliratx.com)



Zelira Therapeutics Ltd is a leading global biopharmaceutical company manufacturing and marketing cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world's largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain as well as offering over the counter (OTC) products.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Louisiana and Washington D.C. with other States in the US expected to follow.

Zelira is also generating revenue in Australia and Germany from its proprietary and patented Zenivol® - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol® has successfully completed the world's first cannabinoid-based efficacy trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial was published in the prestigious peer-reviewed journal SLEEP®.

In 2020, Zelira partnered with SprinJene® Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company has worked in partnership with world-leading researchers and organisations, which since inception include Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

